In a new analysis from the Phase III FLOW trial presented at the European Renal Association congress, Novo Nordisk's once-weekly Ozempic (semaglutide) improved health-related quality of life in 3,533 adults with type 2 diabetes and chronic kidney disease (CKD), translating to about eight additional days per year in full health. After two years, health utility scores stayed stable with Ozempic but declined with placebo, for a significant treatment difference of +0.021.

Why It Matters To Oncology

• Supportive-care and survivorship endpoints are gaining weight across oncology drug discovery, making patient-reported quality-of-life gains increasingly relevant to trial design and value discussions.

• The CKD signal reinforces broader interest in GLP-1 medicines, which are already being explored for effects on metabolic health, treatment tolerance and comorbidity management in cancer populations.

• It also highlights how chronic kidney disease can shape eligibility, dosing and outcomes in oncology, especially for patients receiving nephrotoxic therapies.

The Financials

• The findings add to Ozempic's expanding evidence base after FLOW previously showed a 24% reduction in major kidney disease events and a 20% reduction in all-cause mortality versus placebo over a median 3.4 years.

• That broader package helped support a label expansion in CKD, potentially strengthening Novo Nordisk's position in a large cardiometabolic and renal market.

• Separately, South Korea's OliX Pharmaceuticals raised about KRW 110 billion ($71 million) to advance its siRNA pipeline, including partnered and wholly owned assets.

• And in oncology commercialization, NICE recommended NHS funding for AbbVie's Elahere in folate receptor-alpha-positive platinum-resistant ovarian cancer.

What They're Saying

• Lead author Johannes Mann said the new FLOW quality-of-life data confirm that semaglutide's benefits extend beyond traditional clinical endpoints to outcomes that matter directly to patients.

• NICE said Elahere is the first new NHS-recommended treatment in more than 20 years for resistant ovarian cancer.

What's Next

• Clinicians will watch for publication of the full FLOW quality-of-life analysis and whether regulators, payers and guideline groups incorporate these patient-reported outcomes more explicitly.

• For oncology, the bigger question is whether similar patient-centered measures will play a larger role in development programs for cancer and supportive-care drugs.

• OliX is expected to use its new financing to push its OASIS-enabled siRNA assets forward across metabolic, ophthalmic and dermatologic indications.

• AbbVie's Elahere will be available immediately through the Cancer Drugs Fund before moving to routine NHS commissioning after final guidance.